MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers

Documenti analoghi

• Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
  di: Gu, Jiajia, et al.
  Pubblicazione: (2020)
• ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
  di: Li, Yiting, et al.
  Pubblicazione: (2019)
• Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
  di: Zang, Hongjing, et al.
  Pubblicazione: (2020)
• Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
  di: Zang, Hongjing, et al.
  Pubblicazione: (2020)
• Overcoming acquired resistance to AZD9291, a third generation EGFR inhibitor, through modulation of MEK/ERK-dependent Bim and Mcl-1 degradation
  di: Shi, Puyu, et al.
  Pubblicazione: (2017)